Our previous studies have found that activation of Wnt/ b-catenin signaling resulted in mouse prostatic intraepithelial neoplasia (mPIN). In the large probasin promoter directed SV40-large T-antigen (LPB-Tag) expressing mouse prostate, mPIN forms with rare areas of adenocarcinoma. Combining expression of both Wnt-signaling and Tag expression in the mouse prostate, we have studied the role of Wnt/b-catenin signaling in the progression from mPIN to adenocarcinoma. Our results show that the prostates of mice expressing Tag alone or nuclear b-catenin alone developed mPIN, whereas the activation of both Tag and the Wnt/b-catenin pathway resulted in invasive prostate adenocarcinoma. Furthermore, Foxa2, a forkhead transcription factor, was induced by active Wnt/ b-catenin signaling, and the expression of Foxa2 was associated with the invasive phenotype in the primary prostate cancer. In the LPB-Tag/dominant active (DA) b-catenin prostates, MMP7, a Wnt/b-catenin target gene, was upregulated. Furthermore, we also assessed AR and AR signaling pathway in these LPB-Tag/DA b-catenin mice. Although b-catenin is a well-known AR co-activator in vitro, our study provides strong in vivo evidences indicating that both AR protein and the AR pathway were downregulated in the prostate of LPB-Tag/DA b-catenin mice. Histological analysis shows that prostate sections derived from the LPB-Tag/DA b-catenin mice display neuroendocrine differentiation (NED), but NE cancer does not develop. Together, our findings indicate that Wnt/b-catenin signaling has an important role in the progression of mPIN to prostate adenocarcinoma.
Introduction
Several genes and signaling pathways have been implicated in prostate cancer (PCa) initiation and progression, such as p53, cMyc, Nkx3. 1, Pten, androgen receptor (AR) and Wnt/b-catenin (Kasper, 2005) . Mouse models established by manipulating these genes have been used to study molecular events important for PCa initiation and progression. The SV40 early region (expresses the large T and small t-antigen) has been widely used to establish mouse models for human cancers. Studies have shown that the SV40 large T-antigen interacts with p53 and Rb to inactivate these genes (Levine and Momand, 1990) , thus, altering cellcycle progression to contribute to the rapid cell proliferation. A recent study showed that transgenic mouse models of breast, prostate and lung cancer that express the SV40 early region have a gene signature highly predictive for cancer prognosis (Deeb et al., 2007) , re-enforcing the importance of these mouse models in cancer research. The large probasin (LPB) promoter drives prostate-specific expression of the SV40 large T-antigen (Tag) in transgenic mice. The LPB-Tag lines use a deletion construct of the SV40 early region that removes expression of the small t-antigen. These lines develop high-grade prostatic intraepithelial neoplasia (HGPIN) (Kasper et al., 1998) . Among the six LPB-Tag founder lines that developed HGPIN in the prostate (not including the 12T-10 line that developed small cell carcinoma), the 12T-7 line is the best characterized (Kasper et al., 1998; Masumori et al., 2001) . As a result of a copy number difference on multiple chromosomes, the 12T-7 line diverged into 12T-7 fast (f) and 12T-7 slow (s). The 12T-7f line of mice received additional copies of the Tag gene from the founder than the 12T-7s line. As a result, HGPIN develops faster in the 12T-7f line than in 12T-7s, and death occurs at 17-20 weeks for 12T-7f, and 20-22 weeks for 12T-7s.
Wnt/b-catenin signaling has been implicated in both normal prostate development and in PCa progression (Yu et al., 2009) . Wnts are a family of secreted glycoproteins consisting of 19 members in mammals (Miller, 2002) . In the canonical Wnt pathway, nuclear b-catenin mediates Wnt-signaling. Wnt-signaling prevents b-catenin degradation and results in cytoplasmic/ nuclear accumulation of b-catenin (Miller, 2002) . Once b-catenin enters the nucleus, it functions as a transcription co-activator and activates TCF target genes such as c-Myc, cyclin D1, MMP7, uPA and AR target genes (Miller, 2002; Terry et al., 2006) . Studies have reported that increased nuclear b-catenin is associated with advanced stage PCa (Chesire et al., 2002; de la et al., 2003; Yardy and Brewster, 2005) . As a correlate, previous studies have shown that WIF1 (a Wnt inhibitor) is often down regulated in PCa (Wissmann et al., 2003) . Although mutations in exon 3 of the b-catenin gene that result in the constitutive activation of the Wnt pathway are reported in only 5% of primary PCa (Chesire et al., 2000) , several studies indicate Wnt/ b-catenin signaling can be activated in PCa by a number of additional mechanisms, such as cross-talk with the PTEN/Akt, COX-2/PGE2, PDGF, and NF-kB pathways (Lamberti et al., 2001; Persad et al., 2001; Castellone et al., 2005) . Reactive stroma is associated with PCa in the tumor microenvironment, and there is increasing evidence indicating that Wnt/b-catenin can also be activated by growth factors and inflammatory factors secreted by fibroblasts and macrophages from the tumor microenvironment (Huang and Du, 2008) . In summary, a variety of mechanisms activate Wntsignaling, thus contributing to b-catenin-driven PCa progression in vivo.
We have reported that the activation of Wnt/ b-catenin in the prostate results in HGPIN (Yu et al., 2009) . To study the role of Wnt/b-catenin signaling in PCa progression, a non-degradable b-catenin gene was expressed in mouse prostate in the presence of SV40 large T-antigen. The results showed that the prostatespecific activation of both LPB-Tag and Wnt/b-catenin pathways resulted in the development of invasive adenocarcinoma, whereas the prostates of mice expressing LPB-Tag alone or b-catenin alone developed HGPIN, which is consistent with our previous report (Yu et al., 2009 ). In the LPB-Tag/DA b-catenin mouse prostates, MMP7 expression levels were elevated; and Foxa2, a forkhead transcription factor that is induced by active Wnt/b-Catenin signaling (Yu et al., 2009) , is expressed in the invasive PCa cells. The association of Foxa2 and active Wnt-signaling with PCa invasion suggests that activation of these pathways endows PCa cells with invasive ability, a hallmark of adenocarcinoma formation in the large T-antigen and the Wnt/ b-catenin bigenic mice. Furthermore, we also assessed androgen receptor (AR) expression levels and AR signaling in our bigenic mice. Although b-catenin is a well-known AR co-activator in vitro, our present study provides strong in vivo evidence indicating that both AR protein levels and the AR pathway are in fact, downregulated in the prostates of LPB-Tag/DA b-catenin mice. Finally, there was histological evidence of neuroendocrine differentiation (NED) in the LPBTag/DA b-catenin mouse prostates. Although human prostate neuroendocrine (NE) cancer is rare, NED is common in advanced prostate adenocarcinoma, and the presence of NED correlates with poor prognosis. In this study, we show that the activation of Wnt/b-catenin can account for the increased NED reported in advanced PCa. Together, our findings indicate that Wnt/b-catenin signaling has an important role in the progression of prostatic intraepithelial neoplasia (PIN) to prostate adenocarcinoma and the appearance of NED in advanced stage disease.
Results
Wnt/b-catenin signaling promotes tumor progression in the prostates of LPB-Tag mice Previously, our laboratory showed that the use of a large fragment of the PB promoter to drive the prostatespecific expression of the large T-antigen resulted in reproducible pathological alterations and PIN (Kasper et al., 1998) . To study whether expression of stabilized b-catenin (active Wnt/b-catenin signaling) promotes tumor progression, we developed 12T-7s/Catnb lox(ex3) / PBCre4 (designated as LPB-Tag/DA b-catenin) mice where Wnt/b-catenin signaling was activated in mouse prostate in the presence of large T-antigen. The DA b-catenin transgenic mouse contains a deletion of exon 3 in b-catenin through the expression of probasin driven Cre, resulting in the blockage of b-catenin degradation and subsequent accumulation of b-catenin in the cytoplasm/nucleus in the prostate. Therefore, the LPB-Tag/DA b-catenin mice have a compound, prostate-specific activation of both large T-antigen and nuclear b-catenin.
All the mice used in this study were killed at 18-20 weeks of age. There are at least seven mice for each genotype. H&E staining of prostate tissue from both LPB-Tag mice and DA b-catenin mice showed epithelial cell expansion and the presence of focally filled prostatic lumens, but prostate epithelial cells in these mice are still confined within glands, indicating the presence of PIN and HGPIN, but not adenocarcinoma in the LPB-Tag or DA b-catenin mouse prostates (Figures 1d-i ). In the LPB-Tag/DA b-catenin mice, the VP (Figure 1l ) displayed a more severe phenotype than the DLP (Figure 1k ) or AP (Figure 1j ). The VP, derived from LPB-Tag/DA b-catenin mice showed epithelial cell invasion into surrounding stroma (Figure 1l ), which was not seen in age-matched LPB-Tag (Figures 1d-f) or DA b-catenin mice (Figure 1g-i) . The invasive cells in LPB-Tag/DA b-catenin mouse prostates were epithelial in origin as they expressed b-catenin, Foxa2 and pancytokeratin (Figures 2a-d) . It is noteworthy that the invading edge and cells scattered among surrounding stroma in LPB-Tag/DA b-catenin mouse prostate were positive for Foxa2 (Figures 2d and e) , which was induced by active Wnt/b-catenin signaling, suggesting that Foxa2 has a role in the focal invasion of PCa. Together, the histology showed that LPB-Tag/DA b-catenin mouse prostates developed an invasive phenotype, a hallmark of adenocarcinoma.
Activation of Wnt/b-catenin downregulates AR and AR signaling pathway b-Catenin is reported as a co-activator of AR (Terry et al., 2006) . To study the cross-talk of active Wnt/ b-catenin signaling with the AR pathway, the expression AR and T-antigen in the LPB-Tag/DA b-catenin mouse and control mouse prostates was assessed by immunostaining and by western blotting analysis. In agreement with our previous report (Yu et al., 2009) , AR protein levels were slightly decreased in DA b-catenin mouse prostates (Figure 3h ) when compared with wild-type (Figure 3b) , or with the LPB-Tag mouse prostates (Figure 3e ). However, a further decrease in AR protein levels was observed in prostates derived from LPB-Tag/DA b-catenin mice (Figures 3k, n and 4b) while AR mRNA levels increased (Figure 4c ). Western blotting analysis (Figure 4a ) also shows that the endogenous b-catenin is degraded while the exon3 deletion in b-catenin results in accumulation of the non-degradable mutated b-catenin. In addition, large T-antigen protein levels were reduced in LPB-Tag/DA b-catenin prostate tissue (Figure 3m and Figure 4d ), and displayed a mutually exclusive expression pattern with Foxa2 (compare *labeled area in Figure 3l with that in Figure 3m , and Figures 3o-r). As the large T-antigen transgene expression is driven by the androgen-responsive probasin promoter, decreased large T-antigen expression potentially results from the decreased levels of AR protein. Thus, both AR levels and the AR signaling pathway are downregulated in the prostates of LPB-Tag/DA b-catenin mice.
MMP7 is elevated in mouse prostates following activation of nuclear b-catenin LPB-Tag/DA b-catenin mice developed invasion, a hallmark of adenocarcinoma. To determine the mechanism(s) to explain the more aggressive phenotype that we observed in the LPB-Tag/DA b-catenin mice, we examined the expression of several known b-catenin target genes, including uPA, MMP7 and MMP9. Comparisons of DA b-catenin mice, LPB-Tag mice or LPB-Tag/DA b-catenin mice with wild-type mice revealed that the expression of uPA and MMP9 was not significantly different (data not shown). However, quantitative reverse transcriptase-PCR revealed that prostatic MMP7 levels were significantly higher in DA b-catenin mice when compared with wild-type control or with LPB-Tag mice (Po0.01) (Figure 5a ). In addition, MMP7 levels were further increased in LPB-Tag/DA b-catenin mice when compared with wild-type control or with LPB-Tag mice (Po0.01) (Figure 5a ). The elevation of MMP7 level in mouse prostates that have nuclear b-catenin was also confirmed by western blot and The LPB-Tag/DA b-catenin mouse prostates display focal areas of neuroendocrine differentiation Studies have shown that NE cells in the wild-type prostate and PCa have little or no AR expression (Sciarra et al., 2003) ; however, AR and PSA expression is still detected in adenocarcinoma that begins to express NE factors and undergoes NED. Additionally, we have reported that Foxa2 expression is associated with prostate NE tumor and NE cells found in the normal adult prostate (Mirosevich et al., , 2006 Gupta et al., 2008; Qi et al., 2010) . The induction of Foxa2 and loss of AR in the LPB-Tag/DA b-catenin mice prompted us to examine the expression of the NE markers synaptophysin and chromogranin A (Chr. A) in these samples. Our analysis showed that synaptophysin was not expressed by luminal epithelial cells in wild-type b-Catenin stabilization correlates with increases in Foxa2 expression and increases in markers of NED To confirm our in vivo finding that activation of Wnt/ b-catenin signaling promoted the development of NED in T-antigen expressing prostate cells, we stably integrated a mutant, non-degradable b-catenin gene into NeoTag1 cells. The NeoTag1 prostate epithelial cell line was derived from 12T-7f mouse line, which is a wellcharacterized mouse model of HGPIN (Wang et al., 2006) . Thus, the NeoTag1 murine prostate cell line has similar characteristics as the LPB-Tag transgenic line from which it has originated (Wang et al., 2006) . Ectopic expression of this mutant b-catenin construct results in cytoplasmic/nuclear accumulation of non-degradable b-catenin, effectively functioning as a dominant active Wnt signal (Barth et al., 1999) . Expression of dominant active b-catenin resulted in the increased expression of the two common NE markers (Sciarra et al., 2003) Chr. A and neuron-specific enolase (NSE) (Figures 7a and b) . These results indicate that stabilization of b-catenin induces NED in NeoTag1 cells. In addition to Chr. A and NSE expression, our previous studies have shown that Foxa2 is associated with NE cancer in mouse models and in human NE PCa (Yu et al., 2005; Mirosevich et al., 2006) . We have also reported that activation of Wnt-signaling results in the expression of Foxa2 in the mouse prostate (Yu et al., 2009) . Therefore, Foxa2 expression was also examined in these NeoTag1/b-catenin cells by western blotting analysis. Foxa2 was induced by overexpression of the non-degradable, dominant active b-catenin (Figure 7a ). Taken together, these data indicate that active Wnt/b-catenin signaling can induce the expression of Foxa2, and increased expression of NED markers in NeoTag1 cells.
Discussion
PCa begins with abnormal growth of prostate epithelial cells. However, the rapid cell proliferation alone is not sufficient to cause cancer transformation as evidenced by several mouse models that display active cell proliferation, but develop PIN instead of PCa (Zhang et al., 1997; Bhatia-Gaur et al., 1999; Song et al., 2002) . Overexpression of growth factors or oncogenes, or inactivation of tumor suppressor genes in these transgenic mice alters cell cycle, thus enabling prostatic cells to proliferate rapidly and form PIN lesions, but is not sufficient to form PCa. These pre-cancerous cells generally need to acquire a second mutation or 'hit' to acquire the ability to invade into the surrounding stromal tissue and form malignant PCa (Kasper, 2005) , as observed in the Tag-Hepsin (Klezovitch et al., 2004) Kim et al., 2002) mouse models. Hepsin is a cell surface serine protease; overexpression of hepsin promotes T-antigen expressing cell invasion at the primary site and metastasis to distal organs. This model supports the involvement of proteases in PCa progression. It is now widely accepted that the process of invading through the basement membrane is a hallmark characteristic of prostate adenocarcinoma, which is accomplished by the destruction of the extracellular matrix, including the basement membrane and connective tissue by proteases (Bonfil et al., 2007) . Increased expression of MMPs and other proteases such as uPA and hepsin has been shown to facilitate tumor cell invasion through the basement membrane to gain access to the vascular bed (Bonfil et al., 2007) . It is also important to note that proteolytic activity can also facilitate angiogenesis, thus providing nutrient supply to tumors, as well as a conduit for the promotion of tumor cell dissemination.
Activation of Wnt/b-catenin signaling has been shown to facilitate the invasive phenotype by endowing cell mobility and inducing the expression of proteases such as MMPs and uPA, thus implicating this pathway in tumor invasion (Polakis, 2000; Brabletz et al., 2005) . In this study, we activated Wnt/b-catenin in the presence of large T-antigen in mouse prostate. We found that compound activation of Wnt/b-catenin and T-antigen resulted in invasive PCa, whereas activation of Wnt/ b-catenin alone or expression of large T-antigen alone caused PIN. Our data indicate that activation of Wnt/ b-catenin signaling in the large T-antigen expressing prostate epithelial cells results in progression from HGPIN to invasive adenocarcinoma.
To identify possible mechanism(s) explaining the more aggressive phenotype seen in the Tag/b-catenin Wnt/b-Catenin promotes PCa progression X Yu et al mouse prostate, we analyzed the expression of several well-known b-catenin target genes (MMP7, MMP9 and uPA) (Crawford et al., 2001) . Expression of MMP7 was found to be elevated in the DA b-catenin mouse and LPB-Tag/DA b-catenin mouse prostates ( Figure 5 ), but not MMP9 or uPA. The MMPs are a family of proteases that catalyze the degradation of extracellular matrix proteins (Wilson and Matrisian, 1996; Fingleton, 2006) , and also process a number of proteins on the cell surface to generate bioactive molecules (Fingleton, 2006) . The MMPs are implicated in several cellular processes including proliferation, migration, differentiation and angiogenesis-all of which have important roles during cancer progression (Fingleton, 2006) . The MMP7 is a membrane-type MMP (MT4-MMP), which is cell membrane-associated instead of being secreted into extracellular matrix. Unlike most other MMPs that are produced by stromal cells, MMP7 is exclusively produced by epithelial cells, and has been associated with cancer initiation and progression (Wilson and Matrisian, 1996) . Although the expression of MMP7 is not associated with invasion phenotype observed in the LPB-Tag/DA b-catenin prostates, the induction of MMP7 by stabilized b-catenin may still contribute to the carcinoma development in these prostates. MMP7 has been shown to be important for processing of growth factor molecules (Fingleton, 2006) . Therefore, MMP7 expression distal to the site of frank invasion may suggest a function for MMP7 in the regulated processing of paracrine growth factors. We also observed that the amount of pro-MMP7 (or inactive MMP7) was decreased in the LPB-Tag/DA bcatenin mouse prostate. This could indicate that there is less inactive MMP7 in the LPB-Tag/DA b-catenin mouse prostate compared with the DA b-catenin mouse prostate. However, more mechanistic studies would be required to confirm this. Our studies show that the prostate-specific activation of both LPB-Tag and Wnt/b-catenin pathways results Figure 6 Compound activation of SV40 large T-antigen and b-catenin causes prostate carcinoma with NED features. H&E staining and immunostaining against Foxa2 and synaptophysin were performed on prostate specimens derived from WT (a-c), LPB-Tag (d-f), DA b-catenin (g-i) and LPB-Tag/DA b-catenin (j-l) mice. Foxa2, which has been associated with NE differentiation in prostate, was expressed in prostate derived from both DA b-catenin mouse (h) and LPB-Tag/DA b-catenin mouse (k), but was not expressed in prostate luminal epithelial cells derived from WT mouse (b), or from LPB-Tag mouse (e). synaptophysin was not expressed in prostate from WT mouse (c) or from LPB-Tag mouse (f), hardly detected in prostate derived from DA b-catenin mouse (i), but was expressed in prostate tissue derived from LPB-Tag/DA b-catenin mouse (l). Arrows in panel j-l indicate cells undergoing NED (positive for synaptophysin and Foxa2, and show hyperchromatic nuclei, granular chromatin and high nuclear/cytoplasmic ratio). Scale bar represents 50 mm. A full colour version of this figure is available at the Oncogene journal online.
in the development of invasive adenocarcinoma (Figures  1-3) , with elements of limited NED, whereas the prostates of mice expressing LPB-Tag alone or bcatenin alone developed HGPIN (Kasper et al., 1998; Yu et al., 2009) . It is noteworthy that our data shows Foxa2 is expressed at the tumor invading edge and in cells scattered among the surrounding stroma (Figure 3 ). These data indicate that the active Wnt/bcatenin signaling and the expression of Foxa2 are associated with PCa tumor invasion at the primary site. A similar phenotype has been described in colorectal cancer, where loss of APC functions and/or oncogenic b-catenin mutations contribute to a majority of colorectal cancer cases. Studies have found that in colorectal cancer, nuclear b-catenin displayed a heterogeneous pattern that membrane expression of b-catenin is associated with well-differentiated central area of colorectal tumors, whereas nuclear b-catenin and its down-stream target genes MMP7, uPA and uPAR are frequently detected in invasive cells, suggesting that growth factors and Wnts from extracellular matrix (tumor microenvironment) may account for the enhanced Wnt/b-catenin signaling in these epithelial cells (Brabletz et al., 2001; Huang and Du, 2008) . The heterogeneous distribution of cells with nuclear b-catenin in the invasive front of tumor mass may confer these cells with malignant capabilities. Similarly, we found that in the prostates of the LPB-Tag/DA b-catenin mouse model, the invasive front and cells scattered in the adjacent stroma were positive for Foxa2, an indicator of active b-catenin signaling in prostate, suggesting that activation of Wnt/b-catenin signaling and the expression of Foxa2 in these cells may endow them invasive ability.
Studies have found that b-catenin is an AR coactivator (Terry et al., 2006) . We have also found that when co-transfected with b-catenin, AR exhibits increased activity on the ARR 2 PB promoter in the presence of DHT (data not shown,), confirming that b-catenin functions as an AR co-activator in transient transfection. Additionally, we have reported that activation of Wnt/b-catenin signaling in the mouse prostate results in an initial early increase in AR activity concomitant with the early development of hyperplasia. However, it is important to point out that with the subsequent development of PIN and HGPIN in this model, epithelial cell AR levels are reduced. Consistent with the altered AR protein levels, an increase in androgen-regulated target genes was observed in earlystage prostatic hyperplasia and downregulated in HGPIN (Yu et al., 2009) . In this study, we report that in the LPB-Tag/DA b-catenin mice, there is a decrease in the androgen receptor levels and in the androgenregulated probasin promoter as seen by decreased Tag levels (Figures 3 and 4) . Although large T-antigen expression is decreased, Foxa2 is now expressed in LPBTag/DA b-catenin mouse prostate. The expression of Foxa2 indicates that Wnt/b-catenin signaling is active in these cells. The mutually exclusive expression pattern of large T-antigen and Foxa2, as detected by IHC, indicates that Tag (directed by AR signaling) is reduced in the cells that have activated Wnt/b-catenin signaling. Interestingly, the level of AR mRNA increases in LPBTag/DA b-catenin prostate but the level of the AR protein decreases (Figure 4 ). This suggests that activation of the Wnt-signaling pathway increases protein degradation pathway(s). For example, we have reported that increased levels of the non-degradable exon 3 deleted b-catenin results in increased levels of F-box b-TrCP ubiquitin ligase, an enzyme that causes the degradation of endogenous b-catenin and functions as a feedback inhibitor to Wnt signaling (Yu et al., 2009 ). In conclusion, continuous Wnt/b-catenin signaling seems to downregulate AR and AR target genes. Although prostatic small cell carcinoma (NE cancer) is rare, NED of prostatic adenocarcinoma is commonly reported and associated with a poor patient outcome (Sciarra et al., 2003; Yao et al., 2006; Wang and Epstein, 2008) . Previous studies have shown that the expression of Foxa2 is associated with NE tumors (Mirosevich et al., , 2006 Gupta et al., 2008; Qi et al., 2010) . In addition, several studies have also shown that NE cells in the wild-type prostate and PCa have little or no AR expression, and that loss of AR expression is correlated with NED (Sciarra et al., 2003) . A reduction in AR induced by castration of TRAMP mice results in an increase in the appearance of small cell carcinoma (NE cancer), regardless of the mouse strain used (Huss et al., 2007) . Thus, the loss of AR activity would foster NED, consistent with the fact that small cell carcinomas show no or reduced levels of AR expression. The suppression of AR and AR signaling and the induction of Foxa2 by the activation of Wnt/b-catenin in prostatic PIN provide connections between Wnt/b-catenin pathway and NED of tumors. In our study, we found that the LPB-Tag/ DA b-catenin mouse prostates developed adenocarcinoma with some focal areas showing NE features, suggesting that activation of Wnt/b-catenin in the presence of T-antigen causes prostate NED. This finding was confirmed by in vitro study when a non-degradable b-catenin was expressed in T-antigen expressing NeoTag1 cells. Our results showed that expression of the mutant b-catenin induced NED in these cells as evidenced by the induction of Foxa2 and two other well-established NE markers-NSE and Chr. A. More evidence supporting the involvement of Wnt/b-catenin in prostatic NED comes from an in vitro study showing that activation of Wnt/b-catenin in LNCaP cells resulted in NED, as reflected by the expression of two NE markers, NSE and Chr. A (Yang et al., 2005) . Taken together, these data strongly support the implication of Wnt/b-catenin signaling in NED of prostate adenocarcinoma.
LPB-Tag/DA b-catenin mouse prostates developed HGPIN and prostatic adenocarcinoma, whereas when Tag or nuclear b-catenin alone is targeted to the prostate, the mice developed only PIN to HGPIN. Although we have not seen the development of adenocarcinoma when nuclear b-catenin is targeted to the prostate, another report describes both HGPIN and adenocarcinoma appears when APC is specifically deleted in the mouse prostate (Bruxvoort et al., 2007) , indicating that loss of APC has broader effects than the expression of nuclear b-catenin. In summary, our study found that activation of Wnt/b-catenin signaling in Tantigen expressing prostatic cells promoted the appearance of prostate adenocarcinoma, demonstrating that the role of Wnt-signaling pathway in tumor progression.
Materials and methods
Cell line, plasmids and retroviral infection NeoTag1 cells used in this study were cultured as describe previously (Wang et al., 2006) . The NeoTag1 cell is a prostate epithelial cell line established from ARR 2 PB-Neo/12T-7 Tag transgenic mouse prostate. The large T-antigen immortalized the epithelial cells, and as the ARR 2 PBneo expression is driven by the androgen responsive probasin promoter, the NeoTag1 cells are AR positive with G418 selection. b-Catenin retroviral expression plasmids and control GFP plasmids (empty vector, EV) were kindly provided by Dr Angela Barth (Barth et al., 1999) . The b-catenin gene in this retroviral vector has several point mutations on the putative GSK3b phosphorylation sites (Ser-33, Ser-37, Thr-41 and Ser-45) that prevent b-catenin degradation. For retroviral infection, the b-catenin or control GFP retroviral vector plasmids were transfected into Phoenix packaging cells. After 24 h, culture media were collected and used for infecting NeoTag1 cells. The infection procedure was repeated for three times. b-Catenin or GFP expressing cells were obtained by fluorescence-activated cell sorting.
Mouse lines and mouse breeding 12T-7 is one of the seven LPB-Tag transgenic mouse lines and widely used in PCa research (Kasper et al., 1998) . As a result of a copy number difference on multiple chromosomes, the 12T-7 line diverged into 12T-7f and 12T-7s (Masumori et al., 2001) . In this study, 12T-7s line was used. To get mice with compound activation of LPB-Tag and b-catenin, PBCre4 mice (Wu et al., 2001 ) (on C57BL/6 background) were bred with 12T-7s mice (Kasper et al., 1998) Immunohistochemistry, immunofluorescence staining and western blot Immunostaining, immunofluorescence staining, H&E staining and western blot were conducted as described (Yu et al., 2009) . Antibodies used are: AR and Foxa2 from Santa Cruz (Santa Cruz, CA, USA), syn and b-catenin from BD Biosciences (San Jose, CA, USA), NSE from NeoMarkers (Fremont, CA, USA), large T-antigen from Calbiochem (San Diego, CA, USA), chr. A from ImmunoStar (Hudson, WI, USA), MMP7 from Cell Signaling (Danvers, MA, USA), b-actin from Sigma (St Louis, MO, USA) and wide spectrum cytokeratin (pan-cytokeratin) from Dako (Carpentaria, CA, USA).
Quantitative RT-PCR (qRT-PCR)
RNA was extracted using the RNeasy kit from Qiagen (Valencia, CA, USA). Reverse transcription was conducted using SuperScriptII from Invitrogen (Carlsbad, CA, USA). Primer sequences are: 5 0 -TTTGCCCTTCCTGTGAACAGC-3 0 (f) and 5 0 -CTTGGAGAGCCAGGTCTTGAAGTT-3 0 (r) for Chr. A; 5 0 -GTGGACAACCTCAAGGAAATGCAG-3 0 (f) and 5 0 -TCCACTACGATCCGAGGTAAGTCT-3 0 (r) for MMP7; 5 0 -TGTGGAGATGAAGCTTCTGGCTGT-3 0 (f) and 5 0 -TGG TACAATCGTTTCTGCTGGCAC-3 0 (r) for AR; 5 0 -TGCACC ACCAACTGCTTAGC-3 0 (f) and 5 0 -GGCATGGACTGTGGT CATGAG-3 0 (r) for GAPDH. Real-time PCR was performed on iCycler using iQ SYBR Green Supermix from Bio-Rad (Hercules, CA, USA). PCR was performed as follows: 95 1C for 4 min, followed by 40 cycles of 95 1C/30 s, 58 1C/30 s and 72 1C/ 30s. All samples were normalized by GAPDH. Results were expressed as fold change of each sample versus control.
Abbreviations
PCa, prostate cancer; AR, androgen receptor; HGPIN, highgrade prostatic intraepithelial neoplasia; Tag, large T-antigen; NE, neuroendocrine.
